Management Of Patients With Hepatitis B Virus Reactivation Post–DAA Treatment Of Chronic Hepatitis C Virus Infection In HCV–HBV Coinfected Patients With Pretreatment HBeAg Seroconversion And Early Degree Of Hepatic Fibrosis

References

• Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26(2):162–170. doi:10.1055/s-2006-93975816673294
   PubMed Web of Science ®Google Scholar
• Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. J Gastroenterol Hepatol. 2010;25(2):259–263. doi:10.1111/j.1440-1746.2009.06006.x19817959
   PubMed Web of Science ®Google Scholar
• Mrani S, Chemin I, Menouar K, et al. Occult HBV infection may represent a major risk factor of nonresponse to antiviral therapy of chronic hepatitis C. J Med Virol. 2007;79(8):1075–1081. doi:10.1002/jmv.2094317596829
   PubMed Web of Science ®Google Scholar
• Crespo J, Lozano JL, de la Cruz F, et al. Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. Am J Gastroenterol. 1994;89:1147–1151.8053425
   PubMed Web of Science ®Google Scholar
• Pol S, Haour G, Fontaine H, et al. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017;46:1054–1060. doi:10.1111/apt.1435228994127
   PubMed Web of Science ®Google Scholar
• Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus co-infection in a United States cohort of hepatitis C virus-infected patient. Hepatology. 2013;58:538–545. doi:10.1002/hep.2640023505059
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA. Recommendations for testing, managing and treating hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. Available from: www.Hcvguidelines.org/. Accessed 1211, 2017.
   Google Scholar
• Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology. 2000;32:1106–1110. doi:10.1053/jhep.2000.1928811050062
   PubMed Web of Science ®Google Scholar
• Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34:404–410. doi:10.1053/jhep.2001.2651111481626
   PubMed Web of Science ®Google Scholar
• Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration; Adverse Event Reporting System. Ann Intern Med. 2017;166:792–798. doi:10.7326/M17-037728437794
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236. doi:10.1016/j.jhep.2015.03.02525911336
   PubMed Web of Science ®Google Scholar
• Mostafa AA, El-Shewi ME, Amin AM, Alibiary SHAA. Assessment of CD163 as a predictor of esophageal varices in patients with liver cirrhosis. N Y Sci J. 2016;9:3747.
   Google Scholar
• Gonzalez SA, Perrillo R. Hepatitis B virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy. Clin Infect Dis. 2016;62:S306–S313. doi:10.1093/cid/ciw04327190320
   PubMed Web of Science ®Google Scholar
• Shih CM, Chen CM, Chen SY, Lee Y. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol. 1995;69:1160–1171 [PMC free article] [PubMed].7815494
   PubMed Web of Science ®Google Scholar
• Shih CM, Lo SJ, Miyamura T, Chen SY, Lee Y. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol. 1993;67:5823–5832 [PMC free article] [PubMed].8396658
   PubMed Web of Science ®Google Scholar
• Chen SY, Kao CF, Chen CM, et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem. 2003;278:591–607 [PubMed]. doi:10.1074/jbc.M20424120012401801
   PubMed Web of Science ®Google Scholar
• Schuttler CG, Fiedler N, Schmidt K, Repp R, Gerlich WH, Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol. 2002;37:855–862. doi:10.1016/S0168-8278(02)00296-912445429
   PubMed Web of Science ®Google Scholar
• Dumoulin FL, von Dem Bussche A, Li J, et al. Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology. 2003;305:260–266 [PubMed]. doi:10.1006/viro.2002.176912573571
   PubMed Web of Science ®Google Scholar
• Pan Y, Wei W, Kang L, et al. NS5A protein of HCV enhances HBV replication and resistance to interferon response. Biochem Biophys Res Commun. 2007;359:70–75. doi:10.1016/j.bbrc.2007.05.05217532300
   PubMed Web of Science ®Google Scholar
• Kassas ME, Shimakawa Y, Ali-Eldin Z, et al. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int. 2018;38:2159–2169. doi:10.1111/liv.1387429738637
   PubMed Web of Science ®Google Scholar
• Bhatia M, Gupta E, Choudhary MC, Jindal A, Sarin SK. Evaluation of impact of occult hepatitis B infection in chronic HCV-infected patients: a retrospective cohort study. J Lab Physicians. 2018;10(3):304–308. doi:10.4103/JLP.JLP_12_1830078967
   PubMed Web of Science ®Google Scholar
• Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527. doi:10.1053/jhep.2002.3363812029639
   PubMed Web of Science ®Google Scholar
• Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–834. doi:10.1016/j.amjmed.2003.12.04015178498
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepatol. 2007;14:147–152. doi:10.1111/j.1365-2893.2006.00810.x
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133:1458–1465. doi:10.1053/j.gastro.2007.08.03917935720
   PubMed Web of Science ®Google Scholar
• Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis. Hepatology. 2017;66:13–26. doi:10.1002/hep.2910928195337
   PubMed Web of Science ®Google Scholar
• Mucke VT, Mucke MM, Peiffer KH, et al. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Aliment Pharmacol Ther. 2017;46:432–439. doi:10.1111/apt.1417728627791
   PubMed Web of Science ®Google Scholar
• Mücke MM, Mücke VT, Peiffer K-H, et al. Absence of HBV reactivation in patients with resolved HBV infection following DAA therapy for hepatitis C: a 1-year follow-up study. Open Forum Infect Dis. 2019;6(1):1–5. doi:10.1093/ofid/ofy340
   Web of Science ®Google Scholar
• Odolini S, Lanza P, Angiola A, et al. Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection. New Microbiol. 2017;40:218–220.28513813
   PubMed Web of Science ®Google Scholar